CN103313723A - 肽 - Google Patents
肽 Download PDFInfo
- Publication number
- CN103313723A CN103313723A CN2010800577930A CN201080057793A CN103313723A CN 103313723 A CN103313723 A CN 103313723A CN 2010800577930 A CN2010800577930 A CN 2010800577930A CN 201080057793 A CN201080057793 A CN 201080057793A CN 103313723 A CN103313723 A CN 103313723A
- Authority
- CN
- China
- Prior art keywords
- peptide
- skin
- seq
- acid
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 117
- 239000000203 mixture Substances 0.000 claims abstract description 70
- 206010040829 Skin discolouration Diseases 0.000 claims abstract description 13
- 238000011282 treatment Methods 0.000 claims description 15
- 230000003796 beauty Effects 0.000 claims description 14
- 125000000539 amino acid group Chemical group 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 239000000758 substrate Substances 0.000 claims description 8
- 238000004043 dyeing Methods 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 230000004957 immunoregulator effect Effects 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 238000001212 derivatisation Methods 0.000 claims description 2
- 230000002500 effect on skin Effects 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 24
- 235000013305 food Nutrition 0.000 abstract description 8
- 230000002519 immonomodulatory effect Effects 0.000 abstract description 7
- 230000000699 topical effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 28
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 24
- 239000000463 material Substances 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 12
- 230000008901 benefit Effects 0.000 description 12
- 239000004408 titanium dioxide Substances 0.000 description 12
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 11
- 101710200814 Melanotropin alpha Proteins 0.000 description 11
- -1 amoxy Chemical group 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 11
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 230000036564 melanin content Effects 0.000 description 9
- 239000003605 opacifier Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000007854 depigmenting agent Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 210000002752 melanocyte Anatomy 0.000 description 7
- 239000000344 soap Substances 0.000 description 7
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 230000001166 anti-perspirative effect Effects 0.000 description 6
- 239000003213 antiperspirant Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241001597008 Nomeidae Species 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 229960003512 nicotinic acid Drugs 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 4
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 4
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 4
- 229960003067 cystine Drugs 0.000 description 4
- 239000002781 deodorant agent Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 235000001968 nicotinic acid Nutrition 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 239000003380 propellant Substances 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- WHNFPRLDDSXQCL-UHFFFAOYSA-N α-melanotropin Chemical compound C=1N=CNC=1CC(C(=O)NC(CC=1C=CC=CC=1)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)NC(CCCCN)C(=O)N1C(CCC1)C(=O)NC(C(C)C)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(NC(=O)C(CO)NC(C)=O)CC1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 230000009133 cooperative interaction Effects 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000007761 roller coating Methods 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 230000000475 sunscreen effect Effects 0.000 description 3
- 239000000516 sunscreening agent Substances 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 description 3
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- YDIYEOMDOWUDTJ-UHFFFAOYSA-N 4-(dimethylamino)benzoic acid Chemical compound CN(C)C1=CC=C(C(O)=O)C=C1 YDIYEOMDOWUDTJ-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 108010008364 Melanocortins Proteins 0.000 description 2
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 239000004902 Softening Agent Substances 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical class C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 2
- COVFEVWNJUOYRL-UHFFFAOYSA-N digallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)=C1 COVFEVWNJUOYRL-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000006334 disulfide bridging Effects 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 229910021485 fumed silica Inorganic materials 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000005772 leucine Nutrition 0.000 description 2
- 239000002865 melanocortin Substances 0.000 description 2
- 210000002780 melanosome Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- AQSGIPQBQYCRLQ-UHFFFAOYSA-N (6,6-dihydroxy-4-methoxycyclohexa-2,4-dien-1-yl)-phenylmethanone Chemical compound C1=CC(OC)=CC(O)(O)C1C(=O)C1=CC=CC=C1 AQSGIPQBQYCRLQ-UHFFFAOYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- 150000005207 1,3-dihydroxybenzenes Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- HDIFHQMREAYYJW-FMIVXFBMSA-N 2,3-dihydroxypropyl (e)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C\CCCCCCCC(=O)OCC(O)CO HDIFHQMREAYYJW-FMIVXFBMSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 239000004808 2-ethylhexylester Substances 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- JKRDADVRIYVCCY-UHFFFAOYSA-N 2-hydroxyoctanoic acid Chemical compound CCCCCCC(O)C(O)=O JKRDADVRIYVCCY-UHFFFAOYSA-N 0.000 description 1
- HMKKFLSUPRUBOO-IUPFWZBJSA-N 3,4-dihydroxy-5-[3,4,5-tris[[(z)-octadec-9-enoyl]oxy]benzoyl]oxybenzoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC1=C(OC(=O)CCCCCCC\C=C/CCCCCCCC)C(OC(=O)CCCCCCC\C=C/CCCCCCCC)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(O)=O)O)=C1 HMKKFLSUPRUBOO-IUPFWZBJSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 150000005422 4-hydroxybenzoic acid derivatives Chemical class 0.000 description 1
- AMUTYVGRCVFCCD-UHFFFAOYSA-N 5,6-diaminopyridine-3-carboxylic acid Chemical compound NC1=CC(C(O)=O)=CN=C1N AMUTYVGRCVFCCD-UHFFFAOYSA-N 0.000 description 1
- AMEMLELAMQEAIA-UHFFFAOYSA-N 6-(tert-butyl)thieno[3,2-d]pyrimidin-4(3H)-one Chemical compound N1C=NC(=O)C2=C1C=C(C(C)(C)C)S2 AMEMLELAMQEAIA-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 description 1
- 229930195721 D-histidine Natural products 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 229920002707 Digallic acid Polymers 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010024648 Livedo reticularis Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241001508687 Mustela erminea Species 0.000 description 1
- GRXZJHGCYHNCIH-UHFFFAOYSA-N N(=O)OC(C)CCCCCC.C1(=CC=CC=C1)C(=CC(=O)O)C1=CC=CC=C1 Chemical compound N(=O)OC(C)CCCCCC.C1(=CC=CC=C1)C(=CC(=O)O)C1=CC=CC=C1 GRXZJHGCYHNCIH-UHFFFAOYSA-N 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000008931 Tadenan Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229910010413 TiO 2 Inorganic materials 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- GANNOFFDYMSBSZ-UHFFFAOYSA-N [AlH3].[Mg] Chemical class [AlH3].[Mg] GANNOFFDYMSBSZ-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- DNXNYEBMOSARMM-UHFFFAOYSA-N alumane;zirconium Chemical compound [AlH3].[Zr] DNXNYEBMOSARMM-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- KMJRBSYFFVNPPK-UHFFFAOYSA-K aluminum;dodecanoate Chemical compound [Al+3].CCCCCCCCCCCC([O-])=O.CCCCCCCCCCCC([O-])=O.CCCCCCCCCCCC([O-])=O KMJRBSYFFVNPPK-UHFFFAOYSA-K 0.000 description 1
- 229940064734 aminobenzoate Drugs 0.000 description 1
- RZOBLYBZQXQGFY-UHFFFAOYSA-N ammonium lactate Chemical compound [NH4+].CC(O)C([O-])=O RZOBLYBZQXQGFY-UHFFFAOYSA-N 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960002255 azelaic acid Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- DHAZIUXMHRHVMP-UHFFFAOYSA-N butyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCC DHAZIUXMHRHVMP-UHFFFAOYSA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000001524 citrus aurantium oil Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 229940028356 diethylene glycol monobutyl ether Drugs 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 1
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000013003 healing agent Substances 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 235000013847 iso-butane Nutrition 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229940033357 isopropyl laurate Drugs 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 229940089456 isopropyl stearate Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012184 mineral wax Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000003961 organosilicon compounds Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- JCGNDDUYTRNOFT-UHFFFAOYSA-N oxolane-2,4-dione Chemical compound O=C1COC(=O)C1 JCGNDDUYTRNOFT-UHFFFAOYSA-N 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N palmityl palmitate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940044652 phenolsulfonate Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NIXKBAZVOQAHGC-UHFFFAOYSA-N phenylmethanesulfonic acid Chemical compound OS(=O)(=O)CC1=CC=CC=C1 NIXKBAZVOQAHGC-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- XEIOPEQGDSYOIH-MURFETPASA-N propan-2-yl (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC(C)C XEIOPEQGDSYOIH-MURFETPASA-N 0.000 description 1
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 1
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940014903 tadenan Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及新肽以及包含它们的局部用及食品组合物。当局部施用时,所述新肽用于皮肤美白和免疫调节,当以食品组合物方式消耗时,所述新肽用于免疫调节和身体质量调节。
Description
技术领域
本发明涉及新肽以及包含它们的局部用及食品组合物。当局部施用时,所述新肽用于皮肤美白和免疫调节,当以食品组合物方式消耗时,所述新肽用于免疫调节和身体质量调节。
背景技术
全世界人民都想要身体健康和外表显得健康。良好且平衡的生活方式,包括食用卫生食品,运动和尽可能减少外应力如污染、热、尘和紫外线(UV)幅射据信能赋予人们健康的身体。 除了也能使人显得健康的上述生活方式变化之外,人们还使用美容品来改善外貌。促成身体健康和外表显得健康的两个最重要特质在于控制体重(不过重或不过轻)以及裸露皮肤的外貌。尽管营养在控制体重方面起重要的作用,外貌则一定程度上借助于局部施用的美容产品得以控制。
在热带国家,人们通常具有暗色皮肤,他们希望皮肤表观更为美白。远离热带区域生活的人们,例如高加索人,通常具有较亮白的皮肤,他们更喜欢令肤色晒成均匀的棕褐色。他们的皮肤以任何程度暴露于阳光常导致斑点状皮肤,称作雀斑,并且有些情况下他们局部皮肤区域会出现过度色素沉着。
多种美容手段可令肤色更美白或色调均匀。一种常见的手段是将防晒遮光剂(sunscreen)或防晒隔离剂(sunblock)引入美容组合物中。防晒遮光剂通常为有机化合物,它们的作用是经由吸收指定波长范围的太阳紫外辐射从而使该紫外辐射无法到达皮肤表面。紫外辐射据信是皮肤着色或晒黑的原因,倘若晒黑不均匀,消费者不喜欢这种晒黑。防晒隔离剂通常为无机化合物,它们的作用是作为物理屏障以防各种太阳幅射(既包括紫外线又包括可见光)。
另一种常见的手段是将皮肤美白剂引入美容组合物中。皮肤美白剂通常为分子或组合物,它们改变皮肤中经由皮肤中生化转化实现的黑素形成,由此改变皮肤的颜色和表观。在人类皮肤中,黑素色素的形成起源于L-酪氨酸这一氨基酸的聚合,途经一组酶催化的和自发的化学反应。这特别涉及在黑素细胞的黑素小体隔间内存在的酪氨酸酶的作用。黑素小体内容物从该黑素细胞传递至多个周边角质细胞。整个过程受多种激素的影响,在这些激素中促黑激素(MSH)已得以充分的研究。
本发明的发明人一直致力于开发新皮肤美白剂或提供皮肤美白益处的新组合物。在本发明中,他们设法提供了新肽,这些新肽优先与α-MSH(α-促黑激素)结合以致抑制α-MSH结合到黑皮质素(melanocortin)1受体(MC1R)上。这种抑制提供了皮肤美白方面的益处。早先已公开了肽用于皮肤美白的应用,那些肽不同于涉及到靶向黑素细胞的本文所公开肽。
JP 2001 002527(Lion)公开了皮肤外用制剂,其包括基于组合物总重为0.000001~30 wt%的针对黑素细胞的细胞粘着重排剂,例如包括精氨酸-甘氨酸-天门冬氨酸(RGD)序列在内的肽、包括酪氨酸-异亮氨酸-甘氨酸-丝氨酸-精氨酸这一氨基酸序列在内的肽、戊氧基feline、3-脱氮腺苷、甲酰胺衍生物、肌醇多胺、水杨酸和三萜酸的衍生物、乳糖等。
US 5 126 327(Lion)公开了促黑激素抑制剂,其在分子中具有下式氨基酸序列[I]、[II]或[III]:-His-Ser-Arg-Trp- [I],-Trp-Arg-Ser-His- [II],-Leu-Ala-Cys-Ala-Arg- [III],其中His、Ser、Arg、Trp、Leu、Ala和Cys分别代表L-或D-组氨酸、丝氨酸、精氨酸、色氨酸、亮氨酸、丙氨酸和半胱氨酸残基。该申请要求保护促黑激素抑制剂和含有该抑制剂的皮肤外用制剂,该抑制剂预防或治疗由黑素细胞功能增强所致过多黑素产生所引起的黄褐斑和雀斑症状。
本发明的发明人鉴别了新肽,这些新肽易于合成且在一起使用时可额外提供协同益处。经过广泛的涉及到噬菌体展示技术的研究,他们发现了两种具体的肽,具有七元氨基酸序列,具体为:肽(i),其具有特定的低分子量(700~20000),具有如下氨基酸残基:-Leu-Ser-Arg-His-Val-Leu-Gln-(LSRHVLQ);或肽(ii),其具有如下氨基酸残基:-His-Gly-His-Pro-Phe-Ala-Pro-(HGHPFAP),它们优先与 α-MSH(α-促黑激素)结合以致抑制α-MSH结合到MC1R上。此外,当用于局部用或食品组合物时,这些肽还具有免疫调节和身体质量调节的益处。
使用基本局部序列对比检索工具(BLAST)蛋白数据库搜索程序在美国国家生物技术信息中心(NCBI)数据库中进行的检索显示,肽(i)中七元氨基酸这一序列已作为天然物质中大蛋白或多核苷酸的一部分见诸报导,例如见US 7 344 860(Bristol Myers Squibb Co.)和WO 2008 034648(Metanomics)。但其中报导的序列分子量超过27000道尔顿,有时高达65000道尔顿,不能提供本发明预期的皮肤美白及其他益处。据发明人所知,肽(ii)先前未见公开。
因此,本发明的一个目的在于提供新肽,当引入皮肤美白产品中时,其用于皮肤美白。
本发明的另一目的在于提供新肽,当引入皮肤美白产品中时,与单个肽相比,其发挥协同相互作用以用于提供加强的皮肤美白效果。
本发明的再一目的在于提供新肽,其可引入局部用或食品产品中,提供免疫调节和/或身体质量调节之类的益处。
发明内容
根据本发明的第一方面,提供了肽,其选自:
(i)具有SEQ ID NO:1的肽(i),分子量为700~20000道尔顿,其包含如下氨基酸残基:-Leu-Ser-Arg-His-Val-Leu-Gln-(LSRHVLQ);或
(ii)具有SEQ ID NO:2的肽(ii),其包含如下氨基酸残基:-His-Gly-His-Pro-Phe-Ala-Pro-(HGHPFAP)。
根据本发明的优选方面,提供了皮肤美白组合物,其包含本发明第一方面的肽以及美容上可接受的基质。
根据本发明的另一方面,提供了本发明第一方面的肽用于皮肤美白的用途。
根据本发明的另一方面,提供了本发明第一方面的肽用于免疫调节的用途。
根据本发明的另一方面,提供了本发明第一方面的肽用于身体质量调节的用途。
对于本领域普通技术人员,在阅悉以下详细说明和权利要求书后,本发明的这些及其他方面、特性和优点将是显而易见的。为了免生疑问,本发明一个方面的任何特性可以用在本发明的任何其它方面中。用语“包含”意指“包括”而不必是“由...组成”或“由...构成”。换言之,所列步骤或选项不必是穷举的。请注意,以下描述中给出的示例意在阐明本发明,而不意在将本发明限制于那些示例本身。同样,所有百分数是重量/重量百分数,除非另有说明。除操作和对比例中或者另有明确说明的情况之外,本描述中所有指示材料量或反应条件、材料物理特性和/或应用的数字应被理解为经用语“约”修饰。以“x~y”格式表示的数值范围应理解为包括x和y在内。当针对一具体特性以“x~y”格式记述多个优选范围时,应理解也包括组合各边界点而成的所有范围。如本文记载的本发明公开内容应视为涵盖了如同为相互多重从属的所有如权利要求书记载的实施方案,而不论事实发现权利要求无多重从属或冗余与否。
具体实施方式
在本发明中要求保护两个肽,亦即具有SEQ ID NO:1的肽(i)或具有SEQ ID NO:2的肽(ii)。这两个新肽优先与 α-MSH(α-促黑激素)结合以致抑制α-MSH结合到MC1R上。 当这些肽用于局部用或食品组合物时,这种抑制提供皮肤美白、免疫调节和身体质量调节方面的益处。这两个肽经使用噬菌体展示(PD)技术鉴别出来,噬菌体展示(PD)技术是生物技术领域中用以鉴别特异地结合靶分子的肽的方法。将这两个肽从约十亿种可能物质中选出的整个过程包含如下所示步骤:
从极多的可能肽(约有十亿可能)中,首先鉴别出七个独特的肽作为潜在的α-MSH结合物。从这七个肽中,发现有两个肽就α-MSH结合物而言有格外强的结合性,选择这两个肽用于功能益处研究。 然后在黑素含量试验中测试这些肽减少黑素含量的功效亦即潜能。不仅证实了这两个肽能减少黑素含量,而且还注意到它们在一起使用时协同相互作用。
具有SEQ ID NO:1的肽(i)包含呈特定顺序的七元氨基酸,即,-Leu-Ser-Arg-His-Val-Leu-Gln-。重要的是,具有SEQ ID NO:1的肽(i)分子量为700~20000道尔顿。 具有SEQ ID NO:1的肽(i)的分子量优选低于18000道尔顿,更优选低于15000道尔顿,再更优选低于12000道尔顿。具有SEQ ID NO:1的肽(i)的分子量优选高于750道尔顿,更优选高于1000道尔顿,再更优选高于2000道尔顿,最优选高于4500道尔顿。优选范围意欲包括优选的分子量下限与前述优选的分子量上限中任何一个的组合。尤其优选的是,具有SEQ ID NO:1的肽(i)分子量为1000~8000道尔顿。具有SEQ ID NO:1的肽(i)具有上述分子量范围的优点在于:当肽具有如此短链长时,该肽更有可能与α-MSH(α-促黑激素)结合由此抑制α-MSH结合到MC1R上。当蛋白质分子量高于20000时,具有本发明中要求保护的氨基酸序列的蛋白质与α-MSH结合(若可能的话)的概率极低,因此不要求保护。
具有SEQ ID NO:1的肽(i)优选包含如下环状氨基酸残基:
即,所述七元氨基酸残基在两端都具有胱氨酸,这两胱氨酸经二硫键键合在一起。肽的这一优选方面在本文中称作肽(iii),其具有SEQ ID NO:3。
进一步优选的是,具有SEQ ID NO:1的肽(i)包含如下氨基酸残基:
。
上述肽在本文中称作肽(iv),其具有SEQ ID NO:4。该肽是特别优选的,因为已观测到其更稳定。
在本发明中还要求保护具有SEQ ID NO:2的肽(ii),其包含-His-Gly-His-Pro-Phe-Ala-Pro-这一氨基酸序列。尽管对用于本发明中要求保护的各种用途的该肽的分子量没有限制,肽(ii)分子量优选为700~20000道尔顿。具有SEQ ID NO:2的肽(ii)的分子量优选低于18000道尔顿,更优选低于15000道尔顿,再更优选低于12000道尔顿。具有SEQ ID NO:2的肽(ii)的分子量优选高于750道尔顿,更优选高于1000道尔顿,再更优选高于2000道尔顿,最优选高于4500道尔顿。
具有SEQ ID NO:2的肽(ii)优选包含如下环状氨基酸残基:
即,所述七元氨基酸残基在两端都带有胱氨酸,这两胱氨酸经二硫键键合在一起。上述肽在本文中称作肽(v),其具有SEQ ID NO:5。
具有SEQ ID NO:2的肽(ii)进一步优选包含如下氨基酸残基:
上述肽在本文中称作肽(vi),其具有SEQ ID NO:6。对于具有SEQ ID NO:4的肽(iv),已发现,当在一端存在-Gly-这一氨基酸和在另一端存在-Ala-这一氨基酸,在用于适于消费者使用的组合物时提供更稳定的肽(vi)。
前述氨基酸序列概括成表1,其中各X选自二十种氨基酸(其中,除甘氨酸之外,蛋白质中的其余氨基酸均是L-异构体):
甘氨酸 Gly G
丙氨酸 Ala A
缬氨酸 Val V
亮氨酸 Leu L
异亮氨酸 Ile I
丝氨酸 Ser S
苏氨酸 Thr T
苯丙氨酸 Phe F
酪氨酸 Tyr Y
色氨酸 Trp W
半胱氨酸 Cys C
脯氨酸 Pro P
组氨酸 His H
谷氨酸 Glu E
天门冬氨酸 Asp D
谷氨酰胺 Gln Q
天门冬酰胺 Asn N
赖氨酸 Lys K
精氨酸 Arg R
蛋氨酸 Met M
并且m和n各自独立地是0~10、优选0~5、更优选0~2的整数。
表1:氨基酸序列
进一步优选的是,具有SEQ ID NO:1的肽(i)或具有SEQ ID NO:2的肽(ii)用皮肤直染聚合物(skin substantive polymer)衍生化。适宜的皮肤直染聚合物包括聚乙二醇。
根据本发明的另一方面,提供了皮肤美白组合物,其包含本发明第一方面所述的肽以及美容上可接受的基质。
本文所用的“皮肤美白组合物”意在包括用以局部施用于人类皮肤以获得皮肤美白益处的组合物。这样的组合物通常可归类为驻留型(leave-on)或洗去型(rinse off)。本发明组合物可以是液体、露、霜、泡沫、磨砂剂、凝胶、皂条或爽肤水的形式,或者用工具或借助于面膜、垫或贴片进行施用。皮肤美白组合物的非限制性示例包括驻留型润肤露和霜、淋浴凝胶、盥洗用皂条、防汗剂、除臭剂、口红、粉底、睫毛膏、免晒美黑剂和防晒遮光露。本文所用的“皮肤”意在包括面部和身体(例如颈、胸、背、臂、腋窝、手、脚、臀和头皮)上的皮肤。
皮肤美白组合物优选包含0.0001~10 wt%本发明的肽。所述肽含量更优选为0.001~3 wt%,再更优选0.001~1 wt%。
本发明皮肤美白组合物包含美容上可接受的基质。美容上可接受的基质优选为霜、露、凝胶或乳液的形式。
本发明皮肤美白组合物可使用各种美容上可接受的乳化或非乳化系统和介质来制备。一种非常适宜的美容上可接受的基质是霜的形式。特别优选雪花膏。雪花膏通常包含5~25% w/w脂肪酸和0.1~10% w/w皂。雪花膏为皮肤赋予一种非常合意的matty感。特别优选C12~C20脂肪酸,再更优选C14~C18脂肪酸。最优选的脂肪酸是硬脂酸。组合物中的脂肪酸含量更优选为组合物的5~20 wt%。皂包括脂肪酸的碱金属盐如钠或钾盐,最优选硬脂酸钾。皂含量通常为组合物的0.1~10 wt%,更优选0.1~3 wt%。通常,通过取所需量的总脂肪物质并与所需量的氢氧化钾混合来制得雪花膏。皂常在所述混合期间就地形成。
皮肤美白组合物可包含除本发明要求保护的肽之外的皮肤美白剂。其它适宜的皮肤美白剂包括:维生素B3或其衍生物,例如尼克酸、烟酸或烟酰胺,或者其它众所周知的皮肤美白剂,例如芦荟提取物、乳酸铵、熊果苷、壬二酸、曲酸、丁基羟基茴香醚、丁基羟基甲苯、柠檬酸酯、3-联苯丙烷衍生物、2,5-二羟苯甲酸及其衍生物、鞣花酸、茴香提取物、吡喃葡糖基-1-抗坏血酸、葡糖酸、羟基乙酸、绿茶提取物、氢醌、4-羟基茴香醚及其衍生物、4-羟基苯甲酸衍生物、羟基辛酸、柠檬提取物、亚油酸、抗坏血酸基磷酸镁、桑树根提取物、2,4-间苯二酚衍生物、3,5-间苯二酚衍生物、水杨酸、维生素如维生素B6、维生素B12、维生素C或维生素A、二羧酸、间苯二酚衍生物、羟基羧酸如乳酸及其盐例如乳酸钠,和它们的混合物。维生素B3化合物或其衍生物例如尼克酸、烟酸或烟酰胺是更优选的其它皮肤美白剂,最优选烟酰胺。使用时,烟酰胺含量优选为组合物的0.1~10 wt%,更优选0.2~5 wt%。
皮肤美白组合物可优选额外包含一或多种紫外防晒遮光剂。紫外防晒遮光剂可以是无机物或有机物。
多种有机防晒遮光剂适于与本发明必要成分联合使用。适宜的UV-A/UV-B防晒遮光剂包括:2-羟基-4-甲氧基二苯甲酮、辛基二甲基对氨基苯甲酸、双没食子酸三油酸酯(digalloyltrioleate)、2,2-二羟基-4-甲氧基二苯甲酮、4-(双(羟丙基))氨基苯甲酸乙酯、2-氰基3,3-二苯基丙烯酸2-乙基己酯、水杨酸2-乙基己基酯、对氨基苯甲酸甘油酯、水杨酸3,3,5-三甲基环己基酯、氨茴酸甲酯、对二甲氨基苯甲酸或氨基苯甲酸酯、对二甲氨基苯甲酸2-乙基己基酯、2-苯基苯并咪唑-5-磺酸、2-(对二甲基氨基苯基)-5-磺酸基benzoxazoic酸、对甲氧基肉桂酸2-乙基己基酯、丁基甲氧基二苯甲酰甲烷、2-羟基-4-甲氧基二苯甲酮、辛基二甲基对氨基苯甲酸,和它们的混合物。最适宜的有机防晒遮光剂是对甲氧基肉桂酸2-乙基己基酯和丁基甲氧基二苯甲酰甲烷。
安全有效量的防晒遮光剂可用于本发明的皮肤美白组合物中。组合物优选包含约0.1%~约10%、更优选约0.1%~约5%的防晒遮光剂。
有效的无机防晒隔离剂也优选用于本发明。这包括例如氧化锌、氧化铁、二氧化硅诸如煅制二氧化硅、和二氧化钛。
特细二氧化钛,以其两种形态中任何一个存在,即水分散性二氧化钛和油分散性二氧化钛,特别适用于本发明。水分散性二氧化钛是特细二氧化钛,其粒子是无涂层的或经能赋予其亲水表面特性的材料涂覆。此类材料的示例包括氧化铝和硅酸铝。
油分散性二氧化钛是特细二氧化钛,其粒子显示出疏水表面特性,为此目的,其可经金属皂诸如硬脂酸铝、月桂酸铝或硬脂酸锌涂覆或者经有机硅化合物涂覆。
“特细二氧化钛”意指二氧化钛粒子的平均粒度小于100 nm,优选70 nm或以下,更优选10~40 nm,最优选15~25 nm。
通过将水分散性特细二氧化钛和油分散性特细二氧化钛二者的混合物局部施用于皮肤,可实现协同加强保护皮肤的作用以防UV-A和UV-B两射线的不良影响。
就本发明而言,特细二氧化钛是优选的无机防晒隔离剂。优选引入本发明组合物中的防晒隔离剂总量为组合物的0.1~5 wt%。
本发明组合物还可包含其它稀释剂。稀释剂的作用在于为组合物中存在的其它材料充当分散剂或载体,以便在组合物被施用于皮肤时促进所述材料的分布。
除水以外的稀释剂可包括液体或固体软化剂、溶剂、湿润剂、增稠剂和粉末。这些介质类型能单独地使用或者以一或多种介质的混合物方式使用,它们各自的示例如下:
软化剂,诸如硬脂醇、单蓖麻酸甘油酯、貂油、鲸蜡醇、异硬脂酸异丙酯、硬脂酸、棕榈酸异辛酯、硬脂酸异鲸蜡酯、油醇、月桂酸异丙酯、月桂酸己酯、油酸癸酯、十八烷-2-醇、异鲸蜡醇、二十烷醇、二十二烷醇、棕榈酸鲸蜡酯、硅油诸如二甲聚硅氧烷、癸二酸二正丁酯、肉豆蔻酸异丙酯、棕榈酸异丙酯、硬脂酸异丙酯、硬脂酸丁酯、聚乙二醇、三甘醇、羊毛脂、可可脂、玉米油、棉籽油、橄榄油、棕榈仁油、菜籽油、红花籽油、月见草油、大豆油、葵花籽油、鳄梨油、芝麻籽油、椰子油、花生油、蓖麻油、乙酰基化羊毛脂醇、石油膏、矿物油、肉豆蔻酸丁酯、异硬脂酸、棕榈酸、亚油酸异丙酯、乳酸月桂酯、乳酸肉豆蔻酯、油酸癸酯和肉豆蔻酸肉豆蔻酯;
溶剂,诸如乙醇、异丙醇、丙酮、乙二醇单乙醚、二甘醇单丁醚和二甘醇单乙醚;
粉末,诸如白垩、滑石、漂白土、高岭土、淀粉、树胶、胶态二氧化硅 聚丙烯酸钠、四烷基和/或三烷基芳基铵绿土、化学改性硅酸镁铝、有机改性蒙脱土、水合硅酸铝、煅制二氧化硅、聚羧乙烯、羧甲基纤维素钠和乙二醇单硬脂酸酯。
美容上可接受的基质通常为组合物的10~99.9 wt%,优选50~99 wt%,并且当不存在其它美容辅料时其可构成组合物的余量部分。
本发明组合物可包含常规除臭剂基质作为美容上可接受的基质。除臭剂意指在棒、滚涂或推进剂媒介中用于提供个人除臭益处的产品,例如施用在腋窝区域,其可包含或不包含防汗剂。
除臭剂组合物通常可为硬固体、软固体、凝胶、霜和液体形式,并且使用适合于组合物物理特性的施用器施与。
通过滚涂来递送的除臭剂组合物通常包含液体载体。所述液体载体可以是疏水性的,或包含亲水性液体和疏水性液体二者的混合物。它们可以是乳液或微乳液的形式。液体载体或载体混合物常占组合物的30~95 wt%,很多情况下占40~80 wt%。
疏水性液体载体通常可包含一或多种选自熔点不高于25℃且沸点至少100℃的那些硅氧烷、烃、支链脂族醇、酯和醚化学品类别的材料。
可用于本发明组合物的亲水性液体载体通常包含水和/或一或多元醇或水混溶性同系物。一元醇常是短链的,“短链”意指包含至多6个碳,在实践中最常用乙醇,或有时用异丙醇。多元醇通常包含乙二醇或丙二醇,或可使用同系物诸如二甘醇。
保持液态的组合物可利用常规施用器诸如滚涂器施用,或通过泵送或压挤穿过喷雾生成口来施用。这样的组合物可例如使用下文所述的一或多种增稠剂来增稠。
硬固体形式的组合物通常利用胶凝剂或结构化剂来获得,可利用棒型施用器来施用;软固体、凝胶和霜可利用具备施与头的施用器来施用,所述施与头带有至少一个孔,软固体、凝胶或霜能在适度压力下经由该孔挤出。
可用于实现这一途径的适宜增稠剂或胶凝剂采用高粘度的水溶性或分散性材料材料,包括各种乳化剂,和/或用如下材料来增稠或胶凝化:水溶性或水分散性聚合物,包括聚丙烯酸酯,和水溶性或分散性天然聚合物,诸如水溶性多糖或淀粉衍生物,诸如藻酸盐、角叉菜胶、琼脂糖和水分散性聚合物,包括纤维素衍生物。
组合物中所述聚合物的浓度常选择为1~20%,将取决于需要的增稠或结构化程度以及在所述液体/混合物中所选聚合物的效力。
一类结构化剂合乎需要,因其长久以来已验证能产生硬固体且新近用于制造软固体,这类结构化剂包括蜡。在本文中,术语“蜡”不仅用以包括具有蜡质的感觉并且在30~40℃不溶于水而在稍高温度(一般在50~95℃)下熔化的天然来源材料,诸如蜂蜡、小烛树蜡或巴西棕榈蜡,而且还用以包括具有相似特性的材料。此类其它蜡包括烃蜡,例如石蜡、矿物蜡和微晶蜡;合成蜡,诸如2000~10000道尔顿的聚乙烯;天然蜡的蜡状衍生物或蜡状组分。
可使用每一胶凝剂/结构化剂类别内的材料的混合物。
当在本文中使用的除臭剂组合物构成气溶胶组合物时,除如上文所述基质组合物之外,它还包含推进剂,其通常重量比为95:5~40:60,在很多制剂中重量比为90:10~50:50。
推进剂便利地是低沸点材料,一般沸点低于-5℃,例如烷烃诸如丙烷、丁烷或异丁烷,可能包含一小部分戊烷或异戊烷,或者具有相似碳含量的氢氟烃(hydrofluorocarbon)或碳氟化合物。在填充气溶胶罐期间,借助于其中生成的高压使推进剂气体液化。
本发明组合物可附加地包含防汗剂。防汗剂包括如下金属盐:铝、锌、锆和混合锆铝的硫酸盐、氯化物、羟基氯化物、四氯hydrex甘氨酸盐、明矾、甲酸盐、乳酸盐、苯甲基磺酸盐、琥珀酸盐、苯酚磺酸盐等。防汗剂/除臭剂的典型含量为组合物的约0 wt%~约35 wt%、优选约0 wt%~约25 wt%。组合物可进一步包括能够与所述防汗剂金属盐形成络合物的络合剂诸如有机酸或其衍生物。所述络合剂的示例包括但不限于:醋酸、丙酸、草酸、丙二酸、丁二酸、酒石酸、甘氨酸等以及它们的美容上可接受的盐。络合剂的典型含量为组合物的约0 wt%~约15 wt%、优选约0 wt%~约10 wt%。
本发明组合物可包含各种其它任选组分。CTFA美容成分手册(CTFA Cosmetic Ingredient Handbook,第二版,1992,以引用方式全文并入本文)描述了通常用于皮肤护理业的多种非限制性美容和药物成分,它们适合用于本发明组合物中。示例包括:抗氧化剂、粘结剂、生物学添加剂、缓冲剂、着色剂、增稠剂、聚合物、收敛剂、香料、湿润剂、不透明剂、调理剂、去角质剂、pH调节剂、防腐剂、天然提取物、精油、皮肤感知剂、皮肤抚慰剂和皮肤愈合剂。
根据本发明的另一方面,提供了使皮肤美白的方法,包括向皮肤施用本发明第一方面所述的肽。
根据本发明的再一方面,提供了本发明第一方面的肽用于皮肤美白的用途。该用途优选是非治疗性的。
根据本发明的再一方面,提供了本发明第一方面的肽用于免疫调节的用途。该用途可以是治疗性的或非治疗性的,优选非治疗性的。
根据本发明的再一方面,提供了权利要求1所述的肽用于身体质量调节的用途。该用途可以是治疗性的或非治疗性的,优选非治疗性的。
现在通过以下非限制性实施例进一步描述本发明。
实施例
实施例1至7:
使用黑素含量试验测量了多种材料用作皮肤美白剂的能力。实验按以下程序进行:
包含100000新生人类表皮角质细胞(HeKn)(新生包皮角质细胞,来自Cascade Biologicals)和50000深着色的新生人类表皮黑素细胞(HeMnDP)(深着色新生包皮黑素细胞,来自Cascade Biologicals)的2:1比例混合物在24孔细胞培养板中每孔接种,以建立共培养系统。 温育过夜后,细胞用包含测试活性剂的新鲜培养基(未经处理的或介质对照平行地建立)处理,处理后温育72小时。然后移除培养基,替换为80μl二甲基亚砜(DMSO)。板进一步在65℃用DMSO温育1小时,之后研磨孔内容物,将同一样品用于黑素含量试验(在450 nm在板读数器中读数)和蛋白质评估(常规二辛可宁酸(BiCinchoninic Acid)法,试剂盒来自Peirce)试验。黑素含量降低百分率是相对于未经处理的对照而言的。各种材料的黑素含量降低情况示于下表2。
表2
0 | 所加的肽 | 黑素含量降低百分率 |
1 | 未经处理的对照 | 0 |
2 | 42μM肽1 | 5(±2) |
3 | 420μM肽1 | 22(±3) |
4 | 46μM肽2 | 12(±10) |
5 | 460μM肽2 | 细胞毒性 |
6 | 42μM肽1与46μM肽2的混合物 | 43(±2) |
7 | 100μM曲酸 | 19(±1) |
在上表中肽1指:
在上表中肽2指:
表2数据显示,本发明肽降低黑素含量由此提供皮肤美白,这可与过去使用的试剂例如曲酸匹敌。数据还说明,本发明的两种肽间协同相互作用由此赋予加强的皮肤美白效果。
使用与先前所述相似的方法进行了一组独立的实验,以研究数据的可重现性。该组独立实验的数据证实了可重现性。
Claims (13)
1. 肽,其选自:
(i)具有SEQ ID NO:1的肽(i),分子量为700~20000道尔顿,其包含如下氨基酸残基:-Leu-Ser-Arg-His-Val-Leu-Gln-(LSRHVLQ);或
(ii)具有SEQ ID NO:2的肽(ii),其包含如下氨基酸残基:-His-Gly-His-Pro-Phe-Ala-Pro-(HGHPFAP)。
4. 前述权利要求中任一项所述的肽,其中具有SEQ ID NO:1的肽(i)的分子量为1000~8000。
7. 权利要求1所述的肽,其中所述具有SEQ ID NO:1的肽(i)或具有SEQ ID NO:2的肽(ii)用皮肤直染聚合物衍生化,所述皮肤直染聚合物优选为聚乙二醇。
8. 皮肤美白组合物,其包含前述权利要求中任一项所述的肽和美容上可接受的基质。
9. 权利要求8所述的皮肤美白组合物,其包含0.0001~10 wt%的所述肽。
10. 使皮肤美白的方法,包括向皮肤施用前述权利要求1-7中任一项所述的肽。
11. 权利要求1-7中任一项所述的肽用于皮肤美白的用途。
12. 权利要求1-7中任一项所述的肽用于免疫调节的用途。
13. 权利要求1-7中任一项所述的肽用于身体质量调节的用途。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2898/MUM/2009 | 2009-12-16 | ||
IN2898MU2009 | 2009-12-16 | ||
PCT/EP2010/067972 WO2011072991A1 (en) | 2009-12-16 | 2010-11-23 | Peptide |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103313723A true CN103313723A (zh) | 2013-09-18 |
CN103313723B CN103313723B (zh) | 2015-02-04 |
Family
ID=43533119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201080057793.0A Expired - Fee Related CN103313723B (zh) | 2009-12-16 | 2010-11-23 | 肽 |
Country Status (11)
Country | Link |
---|---|
US (1) | US8580920B2 (zh) |
EP (1) | EP2512496B1 (zh) |
JP (1) | JP5752145B2 (zh) |
CN (1) | CN103313723B (zh) |
BR (1) | BR112012013095A2 (zh) |
CA (1) | CA2782131C (zh) |
EA (1) | EA022214B1 (zh) |
ES (1) | ES2541364T3 (zh) |
MX (1) | MX2012007034A (zh) |
WO (1) | WO2011072991A1 (zh) |
ZA (1) | ZA201203722B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3058936B1 (en) * | 2013-10-18 | 2019-02-06 | Universidade do Minho | Peptide composition and uses thereof |
US11712410B2 (en) | 2018-09-05 | 2023-08-01 | K18, Inc. | Composition for improving hair health |
WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0389950A1 (en) * | 1989-03-23 | 1990-10-03 | Lion Corporation | Melanocyte-stimulating hormone inhibitor and external preparation containing the same |
WO2001088088A2 (en) * | 2000-05-18 | 2001-11-22 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9719195D0 (en) * | 1997-09-09 | 1997-11-12 | Unilever Plc | Skin lightening composition |
JP2001002527A (ja) | 1999-06-22 | 2001-01-09 | Lion Corp | 皮膚外用剤組成物 |
US20070060743A1 (en) * | 2001-05-16 | 2007-03-15 | Tang Y Tom | Novel nucleic acids and polypeptides |
WO2004090097A2 (en) | 2003-04-03 | 2004-10-21 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human p2x7 splice variant, hbmyp2x7v |
CA2644273A1 (en) | 2006-04-05 | 2008-03-27 | Metanomics Gmbh | Process for the production of a fine chemical |
FR2900573B1 (fr) * | 2006-05-05 | 2014-05-16 | Sederma Sa | Nouvelles compositions cosmetiques renfermant au moins un peptide contenant au moins un cycle aromatique bloque |
EP2009023A1 (en) * | 2007-06-04 | 2008-12-31 | Rentschler Beteiligungs GmbH | Novel peptides and their use for the treatment of edema |
-
2010
- 2010-11-23 BR BR112012013095A patent/BR112012013095A2/pt not_active IP Right Cessation
- 2010-11-23 CN CN201080057793.0A patent/CN103313723B/zh not_active Expired - Fee Related
- 2010-11-23 EA EA201200889A patent/EA022214B1/ru not_active IP Right Cessation
- 2010-11-23 MX MX2012007034A patent/MX2012007034A/es active IP Right Grant
- 2010-11-23 WO PCT/EP2010/067972 patent/WO2011072991A1/en active Application Filing
- 2010-11-23 ES ES10779020.6T patent/ES2541364T3/es active Active
- 2010-11-23 CA CA2782131A patent/CA2782131C/en active Active
- 2010-11-23 US US13/515,074 patent/US8580920B2/en active Active
- 2010-11-23 JP JP2012543571A patent/JP5752145B2/ja not_active Expired - Fee Related
- 2010-11-23 EP EP10779020.6A patent/EP2512496B1/en not_active Not-in-force
-
2012
- 2012-05-22 ZA ZA2012/03722A patent/ZA201203722B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0389950A1 (en) * | 1989-03-23 | 1990-10-03 | Lion Corporation | Melanocyte-stimulating hormone inhibitor and external preparation containing the same |
WO2001088088A2 (en) * | 2000-05-18 | 2001-11-22 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
Non-Patent Citations (1)
Title |
---|
LE PAPE ELODIE ET AL.: "Regulation of eumelanin/pheomelanin synthesis and visible pigmentation in melanocytes by ligands of the melanocortin 1 receptor", 《PIGMENT CELL AND MELANOMA RESEARCH》 * |
Also Published As
Publication number | Publication date |
---|---|
EA022214B1 (ru) | 2015-11-30 |
ES2541364T3 (es) | 2015-07-17 |
EP2512496B1 (en) | 2015-04-01 |
CN103313723B (zh) | 2015-02-04 |
US20120263665A1 (en) | 2012-10-18 |
MX2012007034A (es) | 2012-07-04 |
CA2782131A1 (en) | 2011-06-23 |
JP5752145B2 (ja) | 2015-07-22 |
EA201200889A1 (ru) | 2013-01-30 |
JP2013514291A (ja) | 2013-04-25 |
US8580920B2 (en) | 2013-11-12 |
WO2011072991A1 (en) | 2011-06-23 |
BR112012013095A2 (pt) | 2017-05-16 |
EP2512496A1 (en) | 2012-10-24 |
ZA201203722B (en) | 2013-08-28 |
CA2782131C (en) | 2018-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6446414B2 (ja) | 半永久的マスカラ組成物 | |
CN103096980B (zh) | 皮肤抗衰老治疗 | |
CN113423470B (zh) | 化妆品配合剂、化妆品及其制造方法 | |
CN103561717B (zh) | 化妆品的制造方法、化妆品用凝胶的制备方法及减少向化妆品原料中配入的高分子增稠剂的使用量的方法 | |
JP4815164B2 (ja) | 保湿剤及びこれを含有する化粧料及び皮膚外用剤 | |
CN102197022B (zh) | 磺基琥珀酸烷基酯混合物及其用途 | |
US20100255044A1 (en) | Method of depositing particulate benefit agents on keratin-containing substrates | |
EP4014958A1 (en) | Coating film-forming composition | |
EP4006110A1 (en) | Pigment including cellulose | |
US7374783B2 (en) | Powders coated with specific lipoamino acid composition and cosmetics containing the same | |
CN103313723B (zh) | 肽 | |
WO2011038022A2 (en) | Methods and compositions for selectively treating skin | |
WO2021132653A1 (ja) | 汚染防止材料 | |
CN115023271B (zh) | 毛发改善方法 | |
CN108129551A (zh) | 具有皮肤美白效果的肽及其用途 | |
CN102639105B (zh) | 个人护理组合物 | |
WO2021132668A1 (ja) | 浸透促進材料 | |
JP7486928B2 (ja) | 化粧品用水性分散体、分散保護剤、化粧品の製造方法 | |
JP2013023488A (ja) | 化粧料用油剤及びそれを配合する化粧料 | |
JP2002029991A (ja) | アルギナーゼ活性促進剤およびそれを含有する皮膚外用剤 | |
WO2024171519A1 (ja) | コレステリック液晶組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210830 Address after: Rotterdam Patentee after: Unilever Intellectual Property Holdings Ltd. Address before: Rotterdam Patentee before: Unilever Nederland B.V. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150204 |
|
CF01 | Termination of patent right due to non-payment of annual fee |